Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar;11(2):490-498.
doi: 10.1111/jdi.13112. Epub 2019 Jul 27.

Increasing risk of diabetes mellitus in postmenopausal women with newly diagnosed primary breast cancer

Affiliations

Increasing risk of diabetes mellitus in postmenopausal women with newly diagnosed primary breast cancer

Chih-Yuan Wang et al. J Diabetes Investig. 2020 Mar.

Abstract

Aims/introduction: We sought to determine if postmenopausal women who develop breast cancer are at increased risk of developing diabetes mellitus.

Materials and methods: The Taiwan National Health Insurance Research Database was searched from 2001 to 2015 for women aged ≥55 years (postmenopausal) with a diagnosis of primary breast cancer. Participants were age-matched with women without breast cancer in a 1:5 ratio. Cox proportional hazards analyses were used to examine associations between breast cancer, risk factors and the development of diabetes mellitus.

Results: A total of 4,607 women with primary breast cancer and 23,035 age-matched controls without breast cancer were included (mean age 58.6 ± 9.1 years). Adjusting for age, income, urbanization, Charlson Comorbidity Index and medical conditions, the risk of diabetes mellitus for participants with breast cancer at 1, 5, 10 and 15 years was 1.70-, 1.34-, 1.27- and 1.24-fold higher, respectively, than for participants without breast cancer (adjusted hazard ratio [aHR] 1.70, 95% confidence interval [CI] 1.40-2.05; aHR 1.34, 95% CI 1.17-1.54; aHR 1.27, 95% CI 1.13-1.44; aHR 1.24, 95% CI 1.11-1.40). The risk of diabetes mellitus at 1 year for breast cancer patients receiving hormone therapy was 1.22-fold higher than in those not receiving hormone therapy (aHR 1.22, 95% CI 0.86-1.74), but without statistical significance.

Conclusions: Postmenopausal women with breast cancer are at increased risk of developing diabetes mellitus, independent of receiving hormone therapy, and should be closely monitored to establish an early diagnosis and therapeutic intervention for improving related outcomes.

Keywords: Breast cancer; Diabetes mellitus; Postmenopausal.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow diagram of participant inclusion.
Figure 2
Figure 2
Adjusted hazard ratio (solid line) and 95% confidence intervals (dashed line) for the incidence of diabetes, breast cancer versus no breast cancer, over time. HR, hazard ratio.
Figure 3
Figure 3
Adjusted hazard ratio (solid line) and 95% confidence intervals (dashed line) for the incidence of diabetes in the breast cancer cohort, receipt of hormonal therapy versus non‐hormonal therapy, over time. HR, hazard ratio.

Similar articles

Cited by

References

    1. Ferlay J, Soerjomataram I, Dikshit R, et al Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359–E386. - PubMed
    1. Ho ML, Hsiao YH, Su SY, et al Mortality of breast cancer in Taiwan, 1971–2010: temporal changes and an age‐period‐cohort analysis. J Obstet Gynaecol 2015; 35: 60–63. - PMC - PubMed
    1. Berkemeyer S, Lemke D, Hense HW. Incidence and mortality trends in German women with breast cancer using age, period and cohort 1999 to 2008. PLoS One 2016; 11: e0150723. - PMC - PubMed
    1. Maruthur NM. The growing prevalence of type 2 diabetes: increased incidence or improved survival? Curr Diabetes Rep 2013; 13: 786–794. - PubMed
    1. Allott EH, Hursting SD. Obesity and cancer: mechanistic insights from transdisciplinary studies. Endocr Relat Cancer 2015; 22: R365–R386. - PMC - PubMed